SLÁVIK, Marek, Petr BURKOŇ, Tomáš KAZDA, Marie BUDÍKOVÁ, M. SLAVIKOVA, E. DVORAKOVA, Petr POSPÍŠIL, J. GOMBOSOVA, P. NAVRATILOVA and Pavel ŠLAMPA. Toxicity and survival outcomes of adjuvant chemoradiation for gastric and gastroesophageal junction cancer patients treated in period 2006-2009: an institutional experience. Neoplasma. Bratislava: Slovenská akademie vied, 2014, vol. 61, No 6, p. 739-746. ISSN 0028-2685. Available from: https://dx.doi.org/10.4149/neo_2014_090.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Toxicity and survival outcomes of adjuvant chemoradiation for gastric and gastroesophageal junction cancer patients treated in period 2006-2009: an institutional experience
Authors SLÁVIK, Marek (703 Slovakia, belonging to the institution), Petr BURKOŇ (203 Czech Republic, belonging to the institution), Tomáš KAZDA (203 Czech Republic, belonging to the institution), Marie BUDÍKOVÁ (203 Czech Republic, belonging to the institution), M. SLAVIKOVA (203 Czech Republic), E. DVORAKOVA (203 Czech Republic), Petr POSPÍŠIL (203 Czech Republic, belonging to the institution), J. GOMBOSOVA (203 Czech Republic), P. NAVRATILOVA (203 Czech Republic) and Pavel ŠLAMPA (203 Czech Republic, guarantor, belonging to the institution).
Edition Neoplasma, Bratislava, Slovenská akademie vied, 2014, 0028-2685.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Slovakia
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 1.865
RIV identification code RIV/00216224:14110/14:00077947
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.4149/neo_2014_090
UT WoS 000345950900013
Keywords in English adjuvant chemoradiation; gastric cancer; early toxicity; late toxicity; survival outcomes
Tags EL OK, podil
Tags International impact, Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 3/2/2015 12:30.
Abstract
Surgical resection is the mainstay of gastric or gastroesophageal junction cancer treatment and has curative potential for patients with early-stage disease. In order to improve the poor survival rates, there are two complementary treatment strategies used at most - perioperative chemotherapy based on UK Magic trial or adjuvant chemoradiation based on INT-0116 trial. Daily treatment decision making should be led also by institutional experiences with toxicity evaluation. We evaluated survival and toxicity outcomes of 47 consecutive patients who underwent adjuvant chemoradiation in our institution in the years 2006-2009. 45Gy in 5 weeks with concurrent two cycles of FUFA Mayo regimen chemotherapy were administrated as part of combined treatment. The acute toxicity was relatively mild (CTCAE scale): grade 2 nausea in 26%, vomiting in 13%, and diarrhoea grade 1 in 15% and general abdominal discomfort in 57% of patients. Grade 3 haematological and infectious complications in 6% and 2% respectively. Late adverse events were as follows: grade 1 esophageal toxicity in 17%, signs of mild chronic esophageal ulceration and esophageal stenosis in 9% of patients (50% of them had tracheoesophageal fistula). The Kaplan-Meier estimate of the median overall survival was 30.5 months with median 25.7 months disease free survival. The overall survival was statistically significantly affected by the amount of removed positive lymph nodes. For the proper evaluation of radiotherapy role in multimodal treatment approach, results of other clinical trials investigating role of concurrent radiotherapy in administration of perioperative chemotherapy will be necessary. Meanwhile, two equally approaches are possible, all having their pros and cons. Institutional toxicity evaluation is recommended in order to provide the best care possible.
Links
CZ.1.07/2.4.00/17.0100, interní kód MUName: A-Math-Net Síť pro transfer znalostí v aplikované matematice
Investor: Ministry of Education, Youth and Sports of the CR, 2.4 Partnership and networks
PrintDisplayed: 7/5/2024 23:54